https://mb.cision.com/Public/18595/3268152/ba9218ae57934300_800x800ar.jpg
** UCB announces changes on Board of Directors
------------------------------------------------------------
Brussels (Belgium), January 15, 2021 =E2=80=93 7:00 AM (CET)=C2=A0
UCB today announces the cooptation of Professor Susan Gasser as new member =
of UCB's Board of Directors effective as of 1 January 2021. Prof Gasser rep=
laces Professor Alice Dautry who reached the statutory age limit early 2020=
and kindly accepted to stay with the Board of UCB until her successor coul=
d replace her. The cooptation of Prof Susan Gasser was conducted in accorda=
nce with both the statutory rules of UCB and the BCCA (Belgian Code of Comp=
anies and Associations). Prof Susan Gasser qualifies as independent Board m=
ember and she is also appointed as a member of the Scientific Committee of =
the Board in replacement of Prof Alice Dautry. The ratification of Susan Ga=
sser=E2=80=99s cooptation and her appointment for a full mandate of 4 years=
will be proposed at the next Annual General Meeting in April 2021.=C2=A0
Mrs Evelyn du Monceau, UCB=E2=80=99s Chair of the Board said: =E2=80=9CUCB=
=E2=80=99s Board of Directors and Executive Committee want to express their=
sincere thanks to Alice Dautry for the pivotal role she has played over th=
e past 5 years. Her role on UCB=E2=80=99s Scientific Committee, deep expert=
ise in cell biology, immunology, receptors and infectious diseases coupled =
with her dedication has greatly helped the company on its transformation an=
d growth journey.=E2=80=9D=C2=A0
Mr Jean-Christophe Tellier, CEO of UCB said: =E2=80=9CI=E2=80=99m delighted=
to welcome Susan Gasser who brings a wealth of experience in various field=
s including biophysics, molecular biology and genetics =E2=80=93 key to UCB=
=E2=80=99s future development. Her roles on renowned scientific review pane=
ls and international advisory roles make her the perfect candidate to help =
guide the company for the coming years.=E2=80=9D
Prof Susan Gasser is a professor at the University of Basel and holds guest=
professorships at the University of Lausanne and the Tokyo Institute of Te=
chnology. She was the Director of the Friedrich Miescher Institute for Biom=
edical Research (FMI) from 2004 to 2019, and continued as an FMI research g=
roup leader until the end of 2020. On February 1, 2021, she becomes Directo=
r of the ISREC Foundation, based in Lausanne, which is dedicated to transla=
tional cancer research. =C2=A0Professor Gasser studied at the University of=
Chicago and completed her PhD at the University of Basel in the field of b=
iochemistry. She was a professor of Molecular Biology at the University of =
Geneva from 2001 =E2=80=93 2004. She has authored more than 250 primary art=
icles and reviews and received numerous awards for her work. A full biograp=
hy can be found on UCB=E2=80=99s corporate website (https://www.ucb.com/inv=
estors/UCB-Governance) .
UCB=E2=80=99s 2021 Annual General Meeting will be held on April 29, 2021.
For further information =C2=A0=C2=A0 =C2=A0
Corporate Communications
Laurent Schots=C2=A0
Media Relations, UCB =C2=A0
T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0
Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 500 people op=
erating in ~ 40 countries, the company generated revenue of =E2=82=AC 4.9 b=
illion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us=
on Twitter: @UCB_news
Forward looking statements =E2=80=93 UCB
This press release contains forward-looking statements including, without l=
imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2=
=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2=
=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate=
s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu=
e=E2=80=9D and similar expressions. These forward-looking statements are ba=
sed on current plans, estimates and beliefs of management. All statements, =
other than statements of historical facts, are statements that could be dee=
med forward-looking statements, including estimates of revenues, operating =
margins, capital expenditures, cash, other financial information, expected =
legal, arbitration, political, regulatory or clinical results or practices =
and other such estimates and results. By their nature, such forward-looking=
statements are not guarantees of future performance and are subject to kno=
wn and unknown risks, uncertainties and assumptions which might cause the a=
ctual results, financial condition, performance or achievements of UCB, or =
industry results, to differ materially from those that may be expressed or =
implied by such forward-looking statements contained in this press release.=
Important factors that could result in such differences include: changes i=
n general economic, business and competitive conditions, the inability to o=
btain necessary regulatory approvals or to obtain them on acceptable terms =
or within expected timing, costs associated with research and development, =
changes in the prospects for products in the pipeline or under development =
by UCB, effects of future judicial decisions or governmental investigations=
, safety, quality, data integrity or manufacturing issues; potential or act=
ual data security and data privacy breaches, or disruptions of our informat=
ion technology systems, product liability claims, challenges to patent prot=
ection for products or product candidates, competition from other products =
including biosimilars, changes in laws or regulations, exchange rate fluctu=
ations, changes or uncertainties in tax laws or the administration of such =
laws, and hiring and retention of its employees. There is no guarantee that=
new product candidates will be discovered or identified in the pipeline, o=
r that new indications for existing products will be developed and approved=
. Movement from concept to commercial product is uncertain; preclinical res=
ults do not guarantee safety and efficacy of product candidates in humans. =
So far, the complexity of the human body cannot be reproduced in computer m=
odels, cell culture systems or animal=C2=A0models. The length of the timing=
to complete clinical trials and to get regulatory approval for product mar=
keting has varied in the past and UCB expects similar unpredictability goin=
g forward. Products or potential products which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to disputes=
between the partners or may prove to be not as safe, effective or commerci=
ally successful as UCB may have believed at the start of such partnership. =
UCB=E2=80=99 efforts to acquire other products or companies and to integrat=
e the operations of such acquired companies may not be as successful as UCB=
may have believed at the moment of acquisition. Also, UCB or others could =
discover safety, side effects or manufacturing problems with its products a=
nd/or devices after they are marketed. The discovery of significant problem=
s with a product similar to one of UCB=E2=80=99s products that implicate an=
entire class of products may have a material adverse effect on sales of th=
e entire class of affected products. Moreover, sales may be impacted by int=
ernational and domestic trends toward managed care and health care cost con=
tainment, including pricing pressure, political and public scrutiny, custom=
er and prescriber patterns or practices, and the reimbursement policies imp=
osed by third-party payers as well as legislation affecting biopharmaceutic=
al pricing and reimbursement activities and outcomes. Finally, a breakdown,=
cyberattack or information security breach could compromise the confidenti=
ality, integrity and availability of UCB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and expressly disclaims any duty to=
update any information contained in this press release, either to confirm =
the actual results or to report or reflect any change in its forward-lookin=
g statements with regard thereto or any change in events, conditions or cir=
cumstances on which any such statement is based, unless such statement is r=
equired pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
GenericFile
UCB Changes on Board of Directors Jan 15 2021 ENG (https://mb.cision.com/Pu=
blic/18595/3268152/9dd6592a1bee8281.pdf)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x58364x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=